MARIA INES SALADO VALDIVIESO-rekin lankidetzan egindako argitalpenak (11)

2016

  1. CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: A case-control study

    Pharmacogenetics and Genomics, Vol. 26, Núm. 2, pp. 66-73

  2. Genetic variants associated with antithyroid drug-induced agranulocytosis: A genome-wide association study in a European population

    The Lancet Diabetes and Endocrinology, Vol. 4, Núm. 6, pp. 507-516

2014

  1. Knowledge upon the emergency contraceptive pill in Spain

    Atencion Farmaceutica, Vol. 16, Núm. 3, pp. 224-228

  2. No differences between men and women in adverse drug reactions related to psychotropic drugs: A survey from France, Italy and Spain

    Fundamental and Clinical Pharmacology, Vol. 28, Núm. 3, pp. 342-348

2013

  1. Hip fracture rates and bisphosphonate consumption in Spain. An ecologic study

    European Journal of Clinical Pharmacology, Vol. 69, Núm. 3, pp. 559-564

2012

  1. Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain

    Frontiers in Genetics, Vol. 3, Núm. NOV

  2. Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): Changes in the consumption pattern following the introduction of extended release methylphenidate

    Pharmacoepidemiology and Drug Safety, Vol. 21, Núm. 4, pp. 435-441

2011

  1. Adverse events associated with pandemic influenza vaccines: Comparison of the results of a follow-up study with those coming from spontaneous reporting

    Vaccine, Vol. 29, Núm. 3, pp. 519-522

  2. Hepatitis colestásica por amoxicilina

    Gastroenterologia y Hepatologia, Vol. 34, Núm. 7, pp. 474-477

2010

  1. Response to rupatadine and heart rhythm disturbances

    Clinical Pharmacology and Therapeutics

2009

  1. Heart rhythm disturbances associated with rupatadine: A case series from the Spanish and Portuguese pharmacovigilance systems

    Clinical Pharmacology and Therapeutics, Vol. 85, Núm. 5, pp. 481-484